WallStSmart

CONMED Corporation (CNMD)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Edwards Lifesciences Corp generates 375% more annual revenue ($6.51B vs $1.37B). EW leads profitability with a 15.4% profit margin vs 4.1%. CNMD appears more attractively valued with a PEG of 1.84. EW earns a higher WallStSmart Score of 55/100 (C).

CNMD

Buy

54

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 6.0Quality: 5.0
Piotroski: 3/9Altman Z: 1.75

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CNMDUndervalued (+27.4%)

Margin of Safety

+27.4%

Fair Value

$58.27

Current Price

$46.30

$11.97 discount

UndervaluedFair: $58.27Overvalued
EWUndervalued (+68.9%)

Margin of Safety

+68.9%

Fair Value

$254.99

Current Price

$84.37

$170.62 discount

UndervaluedFair: $254.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNMD1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

EW3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

Areas to Watch

CNMD4 concerns · Avg: 4.0/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

P/E RatioValuation
25.2x4/10

Moderate valuation

Revenue GrowthGrowth
0.3%4/10

0.3% revenue growth

Altman Z-ScoreHealth
1.754/10

Distress zone — elevated risk

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.6x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : CNMD

The strongest argument for CNMD centers on Price/Book.

Bull Case : EW

The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bear Case : CNMD

The primary concerns for CNMD are PEG Ratio, P/E Ratio, Revenue Growth. Thin 4.1% margins leave little buffer for downturns.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.6x leaves little room for execution misses.

Key Dynamics to Monitor

CNMD profiles as a value stock while EW is a mature play — different risk/reward profiles.

CNMD carries more volatility with a beta of 0.91 — expect wider price swings.

EW is growing revenue faster at 13.6% — sustainability is the question.

EW generates stronger free cash flow (585M), providing more financial flexibility.

Bottom Line

EW scores higher overall (55/100 vs 54/100), backed by strong 15.4% margins and 13.6% revenue growth. CNMD offers better value entry with a 27.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CONMED Corporation

HEALTHCARE · MEDICAL DEVICES · USA

CONMED Corporation, a medical technology company, develops, manufactures and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company is headquartered in Largo, Florida.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?